JNJ · News · 20260915N

Neuropsychiatry Pipeline Progress

JOHNSON & JOHNSON · 2026-09-15 · Importance 31 · Surprise 42

Johnson & Johnson’s partnered depression candidate JNJ-5120/PIPE-307 failed to meet the primary efficacy endpoint in the Phase 2 MOONLIGHT-1 trial for major depressive disorder. The setback follows an earlier failure in a multiple sclerosis trial, increasing development risk for the Contineum Therapeutics partnership. J&J is continuing to evaluate the trial data, while the report indicates the candidate’s failure had a limited impact on Contineum’s valuation because investors remain focused on PIPE-791.

Key facts

• Johnson & Johnson's JNJ-5120, a depression drug candidate partnered with Contineum Therapeutics, failed to meet its primary endpoint in a phase 2 trial for major depressive disorder. source
• The phase 2 MOONLIGHT-1 trial for JNJ-5120/PIPE-307 failed to meet its primary efficacy endpoint. source
• The failure of JNJ-5120 in the phase 2 major depressive disorder trial follows a previous failure in a multiple sclerosis trial. source